Senapati, Jayastu
Kadia, Tapan Mahendra http://orcid.org/0000-0002-9892-9832
Article History
Accepted: 20 January 2022
First Online: 8 March 2022
Compliance with Ethical Standards
:
: Jayastu Senapati declares that he has no conflict of interest. Tapan Mahendra Kadia has received research funding from AbbVie, Agios Pharmaceuticals, Amgen, Genentech, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Sanofi-Aventis; has received compensation for service as a consultant from AbbVie, Agios Pharmaceuticals, Genentech, Jazz Pharmaceuticals, Pfizer, PulmoTech, Cellenkos, Ascentage Pharma Group, GenFleet Therapeutics, Astellas, and AstraZeneca; and has received speaker’s honoraria from CURE Pharmaceutical and Genzyme.
: Not applicable for the present manuscript.